Beacon Investment Advisory Services Inc. Sells 11,804 Shares of Insulet Co. (NASDAQ:PODD)

Beacon Investment Advisory Services Inc. decreased its stake in shares of Insulet Co. (NASDAQ:PODD) by 7.3% during the 4th quarter, according to the company in its most recent filing with the SEC. The firm owned 150,780 shares of the medical instruments supplier’s stock after selling 11,804 shares during the quarter. Insulet accounts for about 1.7% of Beacon Investment Advisory Services Inc.’s investment portfolio, making the stock its 14th biggest position. Beacon Investment Advisory Services Inc. owned about 0.21% of Insulet worth $39,364,000 as of its most recent filing with the SEC.

A number of other large investors have also made changes to their positions in the stock. Dimensional Fund Advisors LP increased its stake in Insulet by 10.0% during the second quarter. Dimensional Fund Advisors LP now owns 146,746 shares of the medical instruments supplier’s stock valued at $29,618,000 after acquiring an additional 13,351 shares during the period. Mercer Global Advisors Inc. ADV bought a new stake in shares of Insulet during the second quarter valued at approximately $158,000. Beck Bode LLC raised its stake in shares of Insulet by 33.6% in the second quarter. Beck Bode LLC now owns 93,187 shares of the medical instruments supplier’s stock valued at $18,805,000 after purchasing an additional 23,426 shares in the last quarter. Pacer Advisors Inc. boosted its stake in Insulet by 36.3% during the second quarter. Pacer Advisors Inc. now owns 6,506 shares of the medical instruments supplier’s stock worth $1,313,000 after buying an additional 1,734 shares in the last quarter. Finally, Sei Investments Co. increased its holdings in Insulet by 148.6% in the 2nd quarter. Sei Investments Co. now owns 29,289 shares of the medical instruments supplier’s stock valued at $5,911,000 after buying an additional 17,507 shares during the period.

Insider Buying and Selling

In other Insulet news, EVP Eric Benjamin sold 12,394 shares of the firm’s stock in a transaction dated Tuesday, January 21st. The stock was sold at an average price of $280.00, for a total transaction of $3,470,320.00. Following the transaction, the executive vice president now owns 11,383 shares in the company, valued at approximately $3,187,240. This trade represents a 52.13 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, CAO Lauren Budden sold 915 shares of the stock in a transaction that occurred on Tuesday, December 10th. The shares were sold at an average price of $275.62, for a total transaction of $252,192.30. Following the completion of the sale, the chief accounting officer now owns 5,733 shares in the company, valued at $1,580,129.46. This represents a 13.76 % decrease in their ownership of the stock. The disclosure for this sale can be found here. 0.47% of the stock is currently owned by insiders.

Insulet Stock Performance

PODD stock opened at $278.89 on Thursday. The stock has a market capitalization of $19.56 billion, a PE ratio of 47.76, a price-to-earnings-growth ratio of 3.47 and a beta of 1.22. The company has a debt-to-equity ratio of 1.21, a current ratio of 3.68 and a quick ratio of 2.80. The company has a 50 day moving average price of $266.52 and a 200 day moving average price of $234.38. Insulet Co. has a fifty-two week low of $160.19 and a fifty-two week high of $282.86.

Insulet (NASDAQ:PODD) last issued its quarterly earnings results on Thursday, November 7th. The medical instruments supplier reported $0.90 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.77 by $0.13. The business had revenue of $543.90 million for the quarter, compared to analyst estimates of $518.50 million. Insulet had a return on equity of 27.98% and a net margin of 21.22%. During the same quarter in the prior year, the firm posted $0.71 earnings per share. Analysts forecast that Insulet Co. will post 3.22 EPS for the current year.

Analyst Ratings Changes

A number of equities analysts have recently commented on PODD shares. Raymond James raised their price objective on shares of Insulet from $213.00 to $260.00 and gave the stock an “outperform” rating in a report on Monday, October 14th. Barclays raised their price target on shares of Insulet from $220.00 to $234.00 and gave the stock an “equal weight” rating in a research note on Monday, November 11th. Canaccord Genuity Group upped their price objective on Insulet from $269.00 to $304.00 and gave the company a “buy” rating in a research note on Monday, December 9th. Morgan Stanley raised their target price on Insulet from $234.00 to $317.00 and gave the stock an “overweight” rating in a research report on Monday, November 11th. Finally, BTIG Research upped their price target on Insulet from $260.00 to $270.00 and gave the company a “buy” rating in a research report on Friday, November 8th. Three investment analysts have rated the stock with a hold rating and thirteen have given a buy rating to the company. Based on data from MarketBeat, the stock has an average rating of “Moderate Buy” and an average price target of $272.81.

Insulet Company Profile

Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes. The company's Omnipod platform includes the Omnipod 5 Automated Insulin Delivery System (Omnipod 5) which includes a proprietary AID algorithm embedded in the Pod that integrates with a third-party continuous glucose monitor to obtain glucose values through wireless bluetooth communication; Omnipod DASH that features a bluetooth enabled Pod that is controlled by a smartphone-like Personal Diabetes Manager with a color touch screen user interface; and Omnipod GO, a standalone, wearable, insulin delivery system that provides a fixed rate of continuous rapid-acting insulin for 72 hours.